Laconext 150 Tablet contains Lacosamide 150mg, an antiepileptic agent indicated for the treatment of partial-onset seizures in patients with epilepsy. Lacosamide acts by selectively enhancing slow inactivation of voltage-gated sodium channels, stabilizing hyperexcitable neuronal membranes and inhibiting repetitive neuronal firing, thereby reducing seizure activity. It is typically prescribed as adjunctive therapy for patients inadequately controlled on other antiepileptic drugs. Laconext 150 Tablet is administered orally, with dosing individualized based on clinical response and tolerability. Common adverse effects may include dizziness, headache, nausea, and diplopia, while serious reactions such as cardiac conduction abnormalities have been reported, necessitating caution in patients with preexisting cardiac conditions. Regular monitoring of cardiac function is recommended during therapy. Lacosamide is metabolized primarily by the liver and excreted via the kidneys; dose adjustments may be required in hepatic or renal impairment. Concomitant use with other central nervous system depressants may potentiate sedative effects. Laconext 150 Tablet should be used under strict medical supervision, with careful consideration of patient history and concurrent medications to optimize therapeutic outcomes and minimize risks. It is contraindicated in patients with known hypersensitivity to lacosamide or any excipients.